8.26 USD
▼-0.14-1.67%
盘后 8.29 +0.36%
2026-09-15
市值
$533.55M
市盈率
61.04
EPS
0.13
股息率
—
52 周区间
6.97 – 14.51
成交量
2.52M
Beta
1.76
目标价
13.93
52W 低 6.9752W 高 14.51
价格走势
公司简介
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, suc...